๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Thiruvananthapuram
Clinical trial register · India

Clinical Trials in Thiruvananthapuram

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1125 matching records held by the registry are in this view. Synced 22 Sep 2026, 03:16 UTC
1125
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
221
Lead sponsors
across recruiting studies
Top sites
New Delhi 334 Mumbai 259 Hyderabad 238 Bangalore 194 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca5 Akero Therapeutics, Inc3 Otsuka Pharmaceutical Development & Commercialization, Inc.2 Bristol-Myers Squibb2 Population Health Research Institute2
Site location
New Delhi334 Mumbai259 Hyderabad238 Bangalore194 Pune189
All 273 locations
Target enrolment
to
30 of 1125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161Myelofibrosis, Anemia
Takeda
Phase 3
324
Gurgaon, Kochi, Thiruvananthapuram, Pune, New Delhi, Rohini, Chennai, Hyderabad
2026-09-02
Recruiting
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
NCT07606066Type 2 Diabetes
AstraZeneca
Observational
2,150
Guntur, Guwahati, Bangalore, Belagavi, Calicut, Kochi, Thiruvananthapuram, Indore
2026-05-06
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2/3
990
Nashik, Thiruvananthapuram, Mumbai, Delhi, Puducherry, Pune
2025-12-31
Recruiting
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
NCT07044687Acute Myeloid Leukemia
AbbVie
Phase 4
100
Gurgaon, Bengaluru, Thiruvananthapuram, Mumbai, Pune, New Delhi, Bhubaneswar, Chennai
2025-07-24
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc.
Phase 3
630
Visakhapatnam, Ahmedabad, Thiruvananthapuram, Mumbai, New Delhi, Bhubaneswar, Madurai, Hyderabad
2025-04-24
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Immutep S.A.S.
Phase 3
756
Bangalore, Bhubaneswar, Chennai, Kolkata, New Delhi, Thane, Thiruvananthapuram, Varanasi
2025-03-21
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression โ‰ฅ 1%
NCT06561386Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
1,000
Badsa, Bengaluru, Thiruvananthapuram, Mumbai, New Delhi, Secunderabad, Varanasi, Howrah
2024-10-07
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Akero Therapeutics, Inc
Phase 3
2,150
Hyderabad, Surat, Vadodara, Mysore, Thiruvananthapuram, Mumbai, Nagpur, Pune
2024-09-04
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
AstraZeneca
Phase 3
1,018
Delhi, Gurugram, Kolkata, Nashik, Surat, Thiruvananthapuram
2024-08-07
Recruiting
'Glycogen Storage Diseases (GSDs) in Indian Children- Establishing an Indian GSD (I-GSD) Registry'
NCT06396546Glycogen Storage Diseases
Institute of Liver and Biliary Sciences, India
Observational
250
Guindy, Ahmedabad, Surat, Srinagar, Bengaluru, Mangalore, Kochi, Thiruvananthapuram
2024-05-02
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Bengaluru, Chandigarh, Delhi, Gurgaon, Mangaluru, Nagpur, New Delhi, Thiruvananthapuram
2024-04-16
Recruiting
The PURI-HF (Air Purifiers on Heart Failure) Trial
NCT05230784Heart Failure
NYU Langone Health
Not applicable
255
Thiruvananthapuram, Delhi, Ludhiana
2024-03-06
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
Ascentage Pharma Group Inc.
Phase 3
333
Bangalore, Haryฤna, Hyderabad, Kolkata, New Delhi, Pune, Thiruvananthapuram
2024-02-05
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
Sanofi
Phase 3
1,655
Chandigarh, Hyderabad, Kochi, Nagpur, Nashik, New Delhi, Shimla, Thiruvananthapuram
2023-12-13
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716NASH With Fibrosis, MASH With Fibrosis
Akero Therapeutics, Inc
Phase 3
1,650
Surat, Vadodara, Mysore, Thiruvananthapuram, Dahegaon, Mumbai, Nagpur, Pune
2023-12-01
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Bengaluru, Delhi, Kolkata, Marg Jaipur, Nagpur, Nashik, Thiruvananthapuram, Vadodara
2023-11-14
Active, closed
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571NASH/MASH, NAFLD/MASLD
Akero Therapeutics, Inc
Phase 3
700
Surat, Vadodara, Thiruvananthapuram, Dahegaon, Mumbai, Nagpur, Pune, New Delhi
2023-11-10
Active, closed
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
NCT06108219Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH)
Corcept Therapeutics
Phase 2
175
Guwahati, Ahmedabad, Rajkot, Surat, Vadodara, Rohtak, Mysore, Thiruvananthapuram
2023-10-25
Recruiting
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
NCT05348876Non-metastatic Castration-resistant Prostate Cancer
Bayer
Phase 4
50
Vijayawada, Visakhapatnam, Nadiฤd, Surat, Belagavi, Bengaluru, Kochi, Thiruvananthapuram
2022-08-03
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Hyderabad, Ahmedabad, Nadiฤd, Bengaluru, Manipal, Kozhikode, Thiruvananthapuram, Pune
2022-04-05
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Ahmedabad, Nadiฤd, Bengaluru, Manipal, Kozhikode, Thiruvananthapuram, Aurangabad, Pune
2022-03-15
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
152
Thiruvananthapuram, Mumbai, Nagpur, Nashik, New Delhi
2021-12-20
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Bangalore, Thiruvananthapuram, Mumbai, Nagpur, Nashik, Pune, Hyderabad
2021-10-04
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
AstraZeneca
Phase 3
866
Bengaluru, Calicut, Kolkata, Marg Jaipur, New Delhi, Surat, Thiruvananthapuram
2020-07-24
Active, closed
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337Medullary Thyroid Cancer
Loxo Oncology, Inc.
Phase 3
291
Thiruvananthapuram, Nashik, Pune, Kolkata, Chandigarh
2020-02-11
Rows per page Showing 1–25 of 30
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-india/city/thiruvananthapuram

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.